Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations

The Journal of Molecular Diagnostics : JMD
Nuria Mencia-TrinchantDuane C Hassane

Abstract

The presence of minimal residual disease (MRD) is widely recognized as a powerful predictor of therapeutic outcome in acute myeloid leukemia (AML), but methods of measurement and quantification of MRD in AML are not yet standardized in clinical practice. There is an urgent, unmet need for robust and sensitive assays that can be readily adopted as real-time tools for disease monitoring. NPM1 frameshift mutations are an established MRD marker present in half of patients with cytogenetically normal AML. However, detection is complicated by the existence of hundreds of potential frameshift insertions, clonal heterogeneity, and absence of sequence information when the NPM1 mutation is identified using capillary electrophoresis. Thus, some patients are ineligible for NPM1 MRD monitoring. Furthermore, a subset of patients with NPM1-mutated AML will have false-negative MRD results because of clonal evolution. To simplify and improve MRD testing for NPM1, we present a novel digital PCR technique composed of massively multiplex pools of insertion-specific primers that selectively detect mutated but not wild-type NPM1. By measuring reaction end points using digital PCR technology, the resulting single assay enables sensitive and specific ...Continue Reading

Citations

Sep 20, 2017·Journal of Clinical Medicine·Gregory W RoloffLaura W Dillon
Oct 14, 2017·Current Hematologic Malignancy Reports·Francesco BuccisanoRoland B Walter
Nov 4, 2017·Current Hematologic Malignancy Reports·Yi Zhou, Brent L Wood
Jan 10, 2018·Frontiers in Pediatrics·Emilie LalondeMarilyn M Li
Mar 29, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mats Ehinger, Louise Pettersson
Jun 14, 2018·Blood Advances·Farhad RavandiSylvie D Freeman
Jan 3, 2020·Current Opinion in Hematology·Giovangiacinto PaternoAdriano Venditti
Nov 9, 2018·International Journal of Molecular Sciences·Fabio ForghieriMario Luppi
Dec 19, 2019·Molecular Diagnosis & Therapy·Fei YangRichard D Press
May 28, 2020·Frontiers in Cell and Developmental Biology·Jennifer M YoestEric J Duncavage
Feb 1, 2020·Current Treatment Options in Oncology·Sebastian SchwindUwe Platzbecker
Aug 10, 2019·Frontiers in Oncology·Maria Teresa VosoFrancesco Buccisano
Dec 7, 2019·Hematology·Sylvie D Freeman, Christopher S Hourigan
Jul 2, 2020·Blood·Brunangelo FaliniMaria Paola Martelli
Apr 8, 2020·Analytica Chimica Acta·Mohammad Kaji YazdiAli Neshastehriz
Jul 27, 2021·Clinics in Laboratory Medicine·Xueyan Chen, Sindhu Cherian
Sep 5, 2021·Journal of Hematology & Oncology·Marisa J L AitkenNicholas J Short
Sep 17, 2021·Frontiers in Oncology·Amanda LopezMichael J Kluk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.